[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[@Sarepta](/creator/twitter/Sarepta)
"News: The U.S. FDA granted Platform Technology Designation to SRP-9003 Sareptas investigational gene therapy for the treatment of LGMD type 2E/R4. This is one of the first programs to receive the technology designation. Read more at"  
![@Sarepta Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::2216555822.png) [@Sarepta](/creator/x/Sarepta) on [X](/post/tweet/1930272306384793816) 2025-06-04 14:35:55 UTC 6163 followers, 7969 engagements


"Today we announced that enrollment & dosing is complete in Study SRP-9003-301 a Phase X multi-national open-label study of investigational candidate SRP-9003 for the treatment of LGMD2E/R4. Data are expected in the first half of 2025"  
![@Sarepta Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::2216555822.png) [@Sarepta](/creator/x/Sarepta) on [X](/post/tweet/1869376529836503101) 2024-12-18 13:37:50 UTC 6162 followers, 3313 engagements


"Today we issued a safety update for our approved gene therapy. Read here:"  
![@Sarepta Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::2216555822.png) [@Sarepta](/creator/x/Sarepta) on [X](/post/tweet/1901979516135780640) 2025-03-18 12:50:28 UTC 6162 followers, 2919 engagements


"Today we shared updates from our clinical programs focused on limb-girdle muscular dystrophy (LGMD) subtypes 2C/R5 2D/R3 and 2E/R4. Read more here:"  
![@Sarepta Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::2216555822.png) [@Sarepta](/creator/x/Sarepta) on [X](/post/tweet/1912122376738779536) 2025-04-15 12:34:34 UTC 6162 followers, 3416 engagements


"On this #RareDiseaseDay were excited to announce the launch of Route XX The Duchenne Scholarship Program. Were awarding up to XX scholarships to individuals living with Duchenne and up to X scholarships to siblings. Learn more:"  
![@Sarepta Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::2216555822.png) [@Sarepta](/creator/x/Sarepta) on [X](/post/tweet/1895475979042369781) 2025-02-28 14:07:44 UTC 6162 followers, 1176 engagements


"Excited to be a partner of the 2025 @MDAorg Clinical & Scientific Conference. Well be there celebrating XX years of #MDA impact & sharing updates on how Sarepta is advancing science for Duchenne and LGMD patients. #MDAconference"  
![@Sarepta Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::2216555822.png) [@Sarepta](/creator/x/Sarepta) on [X](/post/tweet/1900643260193784031) 2025-03-14 20:20:40 UTC 6162 followers, 2765 engagements


"Attending #ASGCT2025 Explore our posters and oral presentations. Learn more here:"  
![@Sarepta Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::2216555822.png) [@Sarepta](/creator/x/Sarepta) on [X](/post/tweet/1923409078182683050) 2025-05-16 16:03:54 UTC 6154 followers, 1550 engagements


"CEO Doug Ingram on Sareptas global licensing and collaboration agreement with Arrowhead Pharmaceuticals and how the agreement will help solidify Sareptas position as a genetic medicine leader"  
![@Sarepta Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::2216555822.png) [@Sarepta](/creator/x/Sarepta) on [X](/post/tweet/1861418651364082108) 2024-11-26 14:36:04 UTC 6162 followers, 1810 engagements


"Today we announced a licensing and collaboration agreement with Arrowhead Pharmaceuticals that will provide Sarepta with exclusive global rights to multiple clinical pre-clinical and discovery stage programs for rare genetic diseases"  
![@Sarepta Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::2216555822.png) [@Sarepta](/creator/x/Sarepta) on [X](/post/tweet/1861380714509267057) 2024-11-26 12:05:19 UTC 6162 followers, 7594 engagements